Enzymes of the UDP-glucuronosyltransferase (UGT) superfamily contribute to the
elimination of drugs from almost all therapeutic classes. Awareness of the importance of …

Telmisartan is an antagonist of the angiotensin II receptor used in the management of
hypertension (alone or in combination with other antihypertensive agents. It belongs to the …

Irbesartan, a potent and selective angiotensin II type-1 (AT1) receptor blocker (ARB), is one
of the representative medications for the treatment of hypertension. Cytochrome P450 (CYP) …

We demonstrate that CYP2D6 copy-number variation (CNV) can be imputed using existing
imputation algorithms. Additionally, we report frequencies of key pharmacogenetic variants …

Methylophiopogonanone A (MOA) is an abundant homoisoflavonoid in the Chinese herb
Ophiopogonis Radix. Recent investigations revealed that MOA inhibited several human …

Telmisartan, a selective inhibitor of angiotensin II receptor type 1 (AT1), demonstrates
nonlinear pharmacokinetics (PK) when orally administered in ascending doses to healthy …

Genetic polymorphisms can exert a considerable impact on drug pharmacokinetics (PK) and
the development of adverse drug reactions (ADR). However, the effect of genetic …

Aims Angiotensin receptor blockers have been shown to reduce heart failure hospitalization
and cardiovascular mortality in men and women with heart failure with reduced ejection …

The aim of this study was to search for associations of genetic variants with celiprolol
pharmacokinetics in a large set of pharmacokinetic genes, and, more specifically, in a set of …

The angiotensin receptor blocker telmisartan slows progression of kidney disease in
patients with type 2 diabetes (T2D), yet many patients remain at high risk for progressive …